Datasheet

CD86 Antibody
CATALOG NUMBER: 8681

Availability: In stock

$0.00
Product Price Options
$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human
HOMOLOGY:Predicted species reactivity based on immunogen sequence: Rabbit: (75%), Mouse: (75%)
TESTED APPLICATIONS:ELISA, IF, IHC-P, WB
APPLICATIONS:CD86 antibody can be used for Western blot at 1 - 2 μg/mL. Antibody can also be used for Immunohistochemistry at 2 μg/mL. For Immunoflorescence start at 20 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1224 - Daudi Cell Lysate
 2) Cat. No. 1207 - Raji Cell Lysate
PREDICTED MOLECULAR WEIGHT:Predicted: 36 kDa

Observed: 68 kDa
SPECIFICITY:At least five isoforms of CD86 are known to exist; this antibody will detect all five isoforms.
IMMUNOGEN:CD86 antibody was raised against a peptide corresponding to 17 amino acids near the center of human CD86.

The immunogen is located within amino acids 160 - 210 of CD86.
HOST SPECIES:Rabbit

Properties

PURIFICATION:CD86 Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:CD86 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:CD86 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:CD86 Antibody: CD86 molecule, B70, B7-2, B7.2, LAB72, CD28LG2
ACCESSION NO.:NP_787058
PROTEIN GI NO.:332634934
OFFICIAL SYMBOL:CD86
GENE ID:942

Background

BACKGROUND:CD86, also known as B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD80, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2).
REFERENCES: 1) Lane P. Regulation of T and B cell responses by modulating interactions between CD28/CTLA-4 and their ligands, CD80 and CD86. Ann NY Acad Sci 1997; 815:392-400.
2) Feucht J, Kayser S, Gorodezki D, et al. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget 2016; 7:76902-19.

For Research Use Only